RealTime Dynamix™: Bone and Mineral Metabolism Q1 2017

This Spherix Global Insights report highlights responses from 201 nephrologists surveyed in March 2017. Nephrologists provided feedback about changes in the hyperphosphatemia space as well as sharing thoughts about recent renal product approvals—Amgen’s Parsabiv and Opko’s Rayaldee.

Click the button below to download highlights from this report.

RTD: Bone and Mineral Metabolism